Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
4 hedge funds and large institutions have $161K invested in Aridis Pharmaceuticals Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
33% less funds holding
Funds holding: 6 → 4 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
78% less capital invested
Capital invested by funds: $725K → $161K (-$564K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$370K |
| 2 |
Millennium Management
New York
|
-$131K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
-$13K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Millennium Management
New York
| $134K | -$131K | -11,473 | -49% |
|
|
2
UBS Group
Zurich,
Switzerland
| $22K | +$2.48K | +217 | +12% |
|
3
Wells Fargo
San Francisco,
California
| $3K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $2K | -$5.33K | -467 | -75% |
|
|
5
Goldman Sachs
New York
| – | -$370K | -28,348 | Closed |
|
|
SPIA
6
Steward Partners Investment Advisory
New York
| – | -$13K | -1,000 | Closed |
|
ARDS Hedge Fund Activity: Q4 2018 in Review
4 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2018, worth a combined $161K — down 78% from $725K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ARDS and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $2.48K. The largest seller was Goldman Sachs, exiting entirely with an estimated $370K sold.
- 4 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2018, down from 6 in Q3 2018.
- Funds reported $161K of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2018, down 78% quarter-over-quarter.
- 0 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2018 and 2 closed out, a net change of -2 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2018 was UBS Group, an estimated $2.48K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2018 was Goldman Sachs, an estimated $370K sold.
Based on aggregated 13F filings for Q4 2018.